Analyst Reco. Summit Therapeutics Inc.

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 09/06/2026 BST			After hours 21:39:41
14.29 ^USD	+1.28%		14.12	-1.19%

06-08	Summit Therapeutics Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:00 AM
06-04	Summit Therapeutics Insider Bought Shares Worth $722,250, According to a Recent SEC Filing	MT

Analyst Reco.

05-22	Summit Therapeutics Shares Fall After HC Wainwright Downgrade	MT
05-22	Bernstein Initiates Summit Therapeutics at Underperform	MT
05-22	HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy	MT
12-17	Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16	MT
20/10/25	Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results	CI
17/09/25	Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target	MT
04/09/25	Guggenheim Initiates Summit Therapeutics at Buy With $40 Price Target	MT
19/08/25	Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target	MT
13/08/25	Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says	MT
01/07/25	UBS Initiates Summit Therapeutics at Buy With $30 Price Target	MT
11/06/25	Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target	MT
08/05/25	TD Cowen Initiates Summit Therapeutics at Buy	MT
26/03/25	Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23	MT
21/03/25	Cantor Fitzgerald Initiates Summit Therapeutics at Overweight	MT
12/03/25	Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target	MT
28/02/25	Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target	MT
08/01/25	Truist Initiates Summit Therapeutics at Buy With $35 Price Target	MT
11/12/24	Wells Fargo Initiates Summit Therapeutics at Overweight With $30 Price Target	MT
06/12/24	Jefferies Initiates Summit Therapeutics at Buy With $31 Price Target	MT
04/11/24	JMP Securities Initiates Summit Therapeutics at Market Outperform With $32 Price Target	MT
27/09/24	Citigroup Downgrades Summit Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $19	MT
03/06/24	Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	MT
07/05/24	Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	MT
26/03/24	Stifel Initiates Summit Therapeutics With Buy Rating, $8 Price Target	MT
18/11/20	SUMMIT THERAPEUTICS : HC Wainwright Downgrades Summit Therapeutics to Neutral from Buy	MT